

AMENDMENT

IN THE CLAIMS:

Please amend the claims as follows:

B1 1. (Twice Amended) A method for reducing a pro-multiple sclerosis (pro-MS) immune response in a human individual, the method comprising administering to the individual a composition, wherein the composition comprises an affinity ligand comprising an antibody which binds to a B cell determinant, wherein the B cell determinant is selected from the group consisting of CD19, CD 20, CD21, CD22, Lym-1, or a determinant expressed only by the B cells and not by immune cells other than B cells, wherein B cells targeted by the method and by the composition are nonmalignant B cells, and wherein the composition is administered in an amount effective to deplete B cells.

B2 6. (Twice Amended) A site-directed method for reducing a pro-multiple sclerosis (pro-MS) immune response in a human individual, the method comprising administering to the individual a composition, wherein the composition comprises an affinity ligand comprising an antibody which binds to a B cell determinant, wherein the B cell determinant is selected from the group consisting of CD19, CD 20, CD21, CD22, Lym-1, or a determinant expressed only by the B cells and not by immune cells other than B cells, wherein B cells targeted by the method and by the composition are nonmalignant B cells, wherein the composition is delivered into an access that directly supplies central nervous tissue undergoing demyelination, and wherein the composition is administered in an amount effective to deplete B cells.

B3 10. (Twice Amended) A method for reducing a pro-multiple sclerosis (pro-MS) immune response in a human individual, the method comprising administering to the individual a composition, wherein the composition comprises an affinity ligand comprising an antibody which binds to a B cell determinant, wherein the B cell determinant is selected from the group consisting of CD19, CD 20, CD21, CD22, Lym-1, or a determinant expressed only by the B cells and not by immune cells other than B cells, wherein B cells targeted by the method and by the composition are nonmalignant B cells, wherein the composition is administered intravenously, and wherein the composition is administered in an amount effective to deplete B cells.

B4 14. (Twice Amended) A method for treating a human individual having multiple sclerosis (MS) and a pro-MS immune response, or having a pro-MS immune response, the method comprising administering to the individual a composition, wherein the composition comprises an affinity ligand comprising an antibody which binds to a B cell determinant, wherein the B cell determinant is selected from the group consisting of CD19, CD 20, CD21, CD22, Lym-1, or a determinant expressed only by the B cells and not by immune cells other than B cells, wherein B cells targeted by the method and by the composition are nonmalignant B cells, and wherein the composition is administered in an amount to effect a reduction in inflammation underlying clinical manifestations of MS.

Please add claims 18-21 as follows:

B5 18. (New) The method according to claim 1, wherein the antibody comprises a monoclonal antibody.

19. (New) The method according to claim 6, wherein the antibody comprises a monoclonal antibody.

20. (New) The method according to claim 10, wherein the antibody comprises a monoclonal antibody.

BS
cancel 21. (New) The method according to claim 14, wherein the antibody comprises a monoclonal antibody.
